Academic Journal
Q1Advanced Drug Delivery Reviews
About Advanced Drug Delivery Reviews
Advanced Drug Delivery Reviews is a scholarly journal published by Elsevier B.V.. SCImago 2025 places it in Q1 with an SJR of 4.015 and an H-index of 405.
Its listed coverage is 1987-2026 and its research categories include Pharmaceutical Science (Q1). The 2025 dataset reports 127 documents and 12320 citations across the latest three-year reporting window.
In the rapidly evolving field of medicine, advanced drug delivery systems have emerged as a groundbreaking innovation, revolutionizing the way therapeutic agents are administered to patients. These systems offer improved efficiency, targeted delivery, and reduced side effects, addressing many of the challenges faced in conventional drug delivery methods. In this article, we explore the significance, types, and benefits of advanced drug delivery systems, as well as their future prospects.
What is Advanced Drug Delivery?
Advanced drug delivery refers to the use of modern technologies to deliver drugs in a controlled and targeted manner, improving their therapeutic efficacy. Traditional methods of drug administration, such as oral tablets or injections, often result in issues like non-targeted delivery, poor bioavailability, and high variability in drug absorption. Advanced drug delivery systems aim to overcome these challenges by providing controlled release, targeting specific sites in the body, and minimizing side effects.
Types of Advanced Drug Delivery Systems
-
Nanoparticle-based Systems
Nanotechnology plays a pivotal role in advanced drug delivery. Nanoparticles are tiny particles (typically 1-100 nanometers) that can be engineered to carry drugs directly to the site of action, enhancing the bioavailability and therapeutic effect. Liposomes, dendrimers, and solid lipid nanoparticles are commonly used for encapsulating drugs and enabling controlled release. -
Targeted Drug Delivery
This method focuses on delivering the drug specifically to the diseased tissue or organ, minimizing the impact on healthy cells. Antibody-drug conjugates (ADCs), peptide-targeted carriers, and nanomaterials are some of the innovative approaches used to achieve targeted delivery. This is particularly effective in treating conditions like cancer, where precision is critical. -
Gene Delivery Systems
Gene therapy involves delivering genetic material into a patient’s cells to correct genetic disorders. Advanced drug delivery systems are vital for ensuring the safe and efficient delivery of genes, such as using viral vectors or non-viral methods like liposomes or nanoparticles. -
Microneedles and Implantable Systems
Microneedles are tiny needles that painlessly deliver drugs through the skin, allowing for self-administration of vaccines or insulin. Additionally, implantable drug delivery systems release drugs over extended periods, offering a convenient and effective solution for chronic conditions like diabetes. -
Biodegradable Polymers
Biodegradable polymers are gaining attention due to their ability to degrade naturally within the body, eliminating the need for removal after the drug has been delivered. These polymers can be used for sustained-release formulations, providing long-term treatment with minimal interventions.
Benefits of Advanced Drug Delivery
-
Enhanced Targeting and Efficacy: By targeting specific areas, advanced delivery systems ensure that the drug reaches the intended site with greater precision, thus increasing therapeutic effectiveness and reducing the need for higher drug doses.
-
Reduced Side Effects: Traditional drug delivery methods often result in systemic side effects due to non-targeted action. Advanced systems minimize off-target effects, improving patient outcomes and quality of life.
-
Improved Patient Compliance: With advancements like controlled-release formulations and microneedles, patients can experience more convenient and less frequent dosing, leading to better adherence to treatment regimens.
-
Personalized Medicine: The ability to deliver drugs in a controlled and individualized manner means that treatments can be tailored to each patient’s unique needs, taking into account genetic factors and disease characteristics.
Future of Advanced Drug Delivery
The future of advanced drug delivery looks promising, with ongoing research and development focusing on further enhancing drug targeting, improving biomaterials, and integrating artificial intelligence for personalized treatments. Innovations like smart drug delivery systems, which respond to environmental changes in the body, and nanorobots capable of delivering drugs directly to cells, are just a glimpse of what’s to come.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
Advanced drug delivery systems (ADDS) have emerged as a revolutionary field within the pharmaceutical and biotechnology industries, aimed at enhancing the therapeutic effectiveness of drugs while minimizing side effects. These systems employ cutting-edge technologies and innovative strategies to improve the way medications are delivered to the body, ensuring that the active ingredients are released at the right time, in the right amount, and at the targeted location. This not only optimizes drug efficacy but also promotes patient compliance.
The Evolution of Drug Delivery Systems
The field of drug delivery has significantly evolved over the past few decades. Traditional drug delivery methods often involve oral tablets or injections that distribute medication systemically. However, these methods can result in several challenges, including suboptimal drug absorption, variable bioavailability, and increased side effects due to the wide distribution of the drug throughout the body.
Advanced drug delivery systems, on the other hand, focus on overcoming these limitations by utilizing novel techniques that include controlled-release, targeted delivery, and nanoparticle-based systems. These innovations ensure that drugs reach the intended target site with higher precision, leading to improved therapeutic outcomes.
Key Technologies in Advanced Drug Delivery
-
Nanoparticles and Nanocarriers
Nanotechnology has revolutionized drug delivery by enabling the development of nanoparticles and nanocarriers. These tiny particles can encapsulate drugs and protect them from degradation, allowing for targeted delivery to specific tissues or organs. Moreover, nanoparticles can cross biological barriers, such as the blood-brain barrier, making them particularly useful for the treatment of neurological diseases. -
Liposomes and Micelles
Liposomes and micelles are lipid-based carriers that can improve drug solubility and enhance the bioavailability of poorly soluble drugs. Liposomes, for instance, can encapsulate both hydrophilic and hydrophobic drugs, making them versatile delivery systems. They also have the potential for prolonged release, reducing the frequency of drug administration. -
Biodegradable Polymers
Biodegradable polymers play a crucial role in controlled drug release. These polymers degrade over time within the body, releasing the drug gradually and ensuring a sustained therapeutic effect. This controlled release can help maintain optimal drug concentrations in the bloodstream and reduce the risk of side effects caused by drug peaks. -
Targeted Drug Delivery
Targeted drug delivery is one of the most promising approaches in advanced drug delivery systems. It involves the use of ligands, antibodies, or other molecules that can bind specifically to receptors on the surface of target cells. This ensures that the drug is delivered directly to the disease site, increasing its effectiveness while minimizing damage to healthy tissues. -
Gene Delivery Systems
Gene therapy and RNA-based treatments are gaining momentum in the field of drug delivery. Advanced drug delivery systems can be used to deliver therapeutic genes or RNA molecules to specific cells or tissues, offering a potential cure for genetic disorders and cancers.
Benefits of Advanced Drug Delivery Systems
-
Improved Bioavailability: By targeting the delivery of drugs directly to the affected area, bioavailability is enhanced, reducing the amount of drug needed to achieve the desired effect.
-
Reduced Side Effects: Targeted delivery minimizes exposure of healthy tissues to the drug, thus lowering the likelihood of side effects.
-
Enhanced Patient Compliance: Controlled-release systems often require less frequent dosing, which can improve patient adherence to prescribed regimens.
-
Personalized Medicine: ADDS allow for more tailored treatments based on individual patient needs, particularly in the context of precision medicine.
Recent Research Articles
Latest publications matched automatically by ISSN.
Engineering peptide-drug conjugates for targeted cancer therapy: design principle, theranostic imaging, and translational challenges
Amit Kumar, Rajeev Sharma, Awesh K. Yadav
2026-12 · DOI: 10.1016/j.addr.2026.115960A toolbox to optimize and scale up microfluidic production of lipid-based nanoparticles
Amr Abostait, Mahmoud Abdelkarim, Arsalan Nikdoost, Pauline Chavrier et al.
2026-12 · DOI: 10.1016/j.addr.2026.115946Engineering responsive polymeric drug delivery systems via bioorthogonal and click chemistry: From molecular design to function
Jaehak Yu, Chenfangfei Shen, Negin Nosrati Asl, Elizabeth R. Gillies et al.
2026-12 · DOI: 10.1016/j.addr.2026.115961From conventional biologics–device combination products to advanced therapies: current state and future trends in patient-centric delivery
Akhilesh Bhambhani, Julie Y Wei, Hairui Zhang, Catherine Shi et al.
2026-12 · DOI: 10.1016/j.addr.2026.115958Intranasal drug delivery to the brain for neurodegenerative diseases: Current efforts and challenges in delivery platforms and modeling
Katherine Y. Bang, Ross Walenga, Steven Chopski, Markham C. Luke et al.
2026-11 · DOI: 10.1016/j.addr.2026.115938Coupling redox regulation with Cancer immunotherapy: The challenge of polyphenol Nanocarriers
Manuela Curcio, Federica Saletta, Ludovica Scorzafave, Marco Fiore et al.
2026-11 · DOI: 10.1016/j.addr.2026.115956The landscape of genetic medicines for in vivo T cell reprogramming
Jens B. Simonsen, Viktor T. Lemgart, Jayesh A. Kulkarni, Dominik Witzigmann et al.
2026-11 · DOI: 10.1016/j.addr.2026.115940From PEG to randomized PEG: a macromolecular strategy tackling PEG immunogenicity
Julian Schmidt, Caroline Bockhard, Lea Simon, Gregor M. Linden et al.
2026-11 · DOI: 10.1016/j.addr.2026.115943Redox-responsive nanomaterials for mRNA delivery: From rational design to therapeutic applications
Meng Li, Yifan Wang, Jing Gao, Soohwan An et al.
2026-11 · DOI: 10.1016/j.addr.2026.115942Beyond PEG: Re-Engineering stealth-polymers to do more than just hide
Rachita Kiran, Fatemeh Kashani Asadi Jafari, Ryan Strauch, Richard d’Arcy et al.
2026-11 · DOI: 10.1016/j.addr.2026.115944Bioactive nanomedicines for multidrug-resistant colorectal cancer: Actionable mechanisms, emerging particle classes, and translational barriers
Milad Rasouli, Fatemeh Babaei, Nadia Fallahhosseini, Adeleh Divsalar et al.
2026-11 · DOI: 10.1016/j.addr.2026.115957Redox-responsive LNPs for therapeutics delivery
You Zhou, Nan Lu, Muhammad Waqqas Hasan, Fei Deng et al.
2026-10 · DOI: 10.1016/j.addr.2026.115934Redox-activated heavy-atom-free photosensitizers for enhanced photodynamic cancer therapy
Hyunsun Jeong, Haoyang Song, Van-Nghia Nguyen, JaeHong Park et al.
2026-10 · DOI: 10.1016/j.addr.2026.115937Enabling formulations for PROTACs: A line-of-sight to clinic
Magda Swedrowska, Rebecca Fransson, Esther Jacobs, Amjad Abouselo et al.
2026-10 · DOI: 10.1016/j.addr.2026.115927Silicone oil in protein drug products and its implications for formulation stability
Deepak Kumar Tripathi, Alexandra Lucas, Vaibhav Upadhyay, Paula Sakemi Fukuhara et al.
2026-10 · DOI: 10.1016/j.addr.2026.115926The intersection of engineered live biotherapeutics, the microbiome, and drug delivery
Nathan Crook, Juliane Nguyen
2026-10 · DOI: 10.1016/j.addr.2026.115939Editorial Board
2026-10 · DOI: 10.1016/s0169-409x(26)00184-5Decoding cellular dynamics and microenvironmental responses in organ-on-chip systems through real-time sensing
Pooja Gupta, Eshira Gupta, Ratnesh Jain, Prajakta Dandekar et al.
2026-10 · DOI: 10.1016/j.addr.2026.115941Microphysiological (“organ-on-a-chip”) models of pulmonary infections for developing novel anti-infectives
Anne Rindchen, Nicole Schneider-Daum, Claus-Michael Lehr
2026-09 · DOI: 10.1016/j.addr.2026.115917Molecular design and delivery of extracellular and membrane protein degradation chimeras
Shutong Lin, Huiling Zhou, Jiayan Qiu, Yijing Dang et al.
2026-09 · DOI: 10.1016/j.addr.2026.115959Reviews
Community Reviews
Version History
April 22, 2025 at 10:35 am
April 22, 2025